NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Running, not enrolling · Phase 1

Conditions studied: Metastatic Neuroendocrine Prostate Cancer

In brief

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the baseline and following targeted radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

Key facts

Study ID

NCT06379217

Run by

Novartis Pharmaceuticals

People needed

31

Starts

2024-07-29

Expected to finish

2026-08-31

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Nebraska Cancer Specialists — Omaha, Nebraska, United States
• Memorial Sloan Kettering Cancer Ctr — New York, New York, United States
• Novartis Investigative Site — Nantes, France
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Rostock, Germany
• Novartis Investigative Site — L'Hospitalet de Llobregat, Barcelona, Spain
• Novartis Investigative Site — Madrid, Spain
• Novartis Investigative Site — Sutton, Surrey, United Kingdom
• Novartis Investigative Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.